Surio Therapeutics Announces Successful Phase Ia Study for First-in-Class Oncology Drug SURIO-001; Advances to Phase Ib Patient Trial
[Hangzhou, May 6th, 2026]
Hangzhou Surio Therapeutics Co., Ltd. (“Surio”), a biopharmaceutical company dedicated to developing first-in-class therapies to address unmet medical needs in oncology, today announced the successful completion of the Phase Ia clinical study for its investigational drug, SURIO-001. The trial, conducted by its subsidiary Avisure, evaluated the drug in healthy subjects.
The study results demonstrated that the ST114 molecule in the SURIO-001 combination exhibited a favorable safety and tolerability profile in healthy subjects with no grade 2 or higher adverse event. Predefined pharmacokinetic objectives were also achieved. These data provide a robust foundation for subsequent clinical investigation in cancer patients. Based on the positive safety and tolerability results from the Phase Ia study, the company will initiate the Phase Ib clinical trial of the drug very soon.
[About SURIO-001]
SURIO-001 is the lead product developed from Surio’s proprietary ATTACK (Active Tissue Targeting via Anchored ClicK chemistry) platform, a combination product comprising of tumor-specific labeling reagent ST114 and cytotoxin conjugate ST205 under development in Surio’s subsidiaryAvisure. Both ST114 and ST205 are developed from the ATTACK technology. ST114 is an unnatural sugar derivative, which could specifically label cancer cells with Clickable artificial receptors through selective recognition by a protein target that is overexpressed in a series of solid tumors with positivity rate more than 30%. ST205 is a tubulin inhibitor conjugate, which could specifically recognize the artificial receptors on cancer cell surface inserted by ST114 through Click Chemistry to achieve targeted payload delivery and treatment. SURIO-001’s potential oncology indications include gastric cancer, biliary tract cancer, bladder cancer, kidney cancer, head and neck cancer, cervical cancer, ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, liver cancer, colorectal cancer, etc.
[About the SURIO-001 Phase Ia Study]
The Phase Ia study of SURIO-001 was a randomized, double-blind, placebo-controlled, single/multiple ascending dose study conducted in healthy volunteers. It was designed to evaluate the safety, tolerability, and pharmacokinetic profile of the ST114 molecule in the SURIO-001 combination in a healthy population.
[About the SURIO-001 Phase Ib Study]
The Phase Ib study aims to further evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of SURIO-001 in patients with advanced solid tumors. The trial recruits patients with locally advanced or metastatic solid tumors confirmed by histopathology or cytology who have failed standard of care, have no standard treatment options, or are not suitable for standard treatment at the current stage, including but not limited to gastric cancer, cholangiocarcinoma, bladder cancer, renal cancer, head and neck cancer, cervical cancer, ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer. This study represents a pivotal step in advancing the clinical development of SURIO-001 and will help determine the appropriate dose and regimen for subsequent confirmatory clinical studies.
[About Surio]
Surio Therapeutics Co. Ltd. was established in early 2019 and is currently located in the Science and Technology Park of Westlake University in Yunxi town, Hangzhou. Surio Therapeutics is committed to developing the First-in-class Active Tissue Targeting via Anchored ClicK chemistry (ATTACK) technology. ATTACK innovatively achieves selective in vivo tissue artificial labeling by unnatural sugar metabolic glycoengineering and then targets the labeling to accomplish targeted drug delivery to otherwise untargetable disease for treatment and diagnostic applications. The company is committed to developing a new generation of precision-targeted drugs through this disruptive technology platform to address unmet clinical needs.
[About Avisure]
Avisure is a joint venture established by Surio Therapeutics and Vivo Capital in late 2025. As one of the inaugural members of the Vivo Accelerator, Avisure is focused on advancing the clinical and commercial development of SURIO-001 and related assets.
[About Vivo Capital And Vivo Accelerator]
Vivo Capital, founded in 1996, is a leading global healthcare investment firm with a comprehensive multi-fund platform spanning venture capital, growth equity, and public markets. With over $7.5 billion in active assets under management and a global portfolio of more than 460 companies, Vivo invests across the healthcare spectrum, including biotech, pharmaceuticals, and medical devices. The firm is headquartered in Palo Alto, California, with additional offices in Beijing, Shanghai, Hong Kong, Taipei, and Singapore.
Launched in August 2025, the Vivo Accelerator is an open, international innovation platform built by Vivo Capital. It leverages Vivo’s deep healthcare ecosystem and global resources to identify and accelerate high-potential projects across all stages of drug development. The accelerator aims to foster collaboration and efficiently advance the R&D and clinical processes of its portfolio companies.